Multipotent adult progenitor cells sustain function of ischemic limbs in mice
J. Clin. Invest. Xabier L. Aranguren, et al. 118:505 doi:10.1172/JCI31153 [Go to this article.]

Figure 4
Late effects of mMAPC-U, mMAPC-VP, and mBMCs in moderate ischemia. (A) Laser Doppler measurements in left legs (expressed as % of the nonligated right leg) of vehicle- (red), mMAPC-U– (black), mBMC- (gray), or mMAPC-VP–treated mice (blue). (B) Swim performance (expressed as % versus day –1 [baseline]) of vehicle- (red), mMAPC-U– (black), mBMC- (gray), or mMAPC-VP–treated mice (blue). (C) Table summarizing clinical evaluation of all treatment regimens up to 5 weeks after transplantation. Representative images (D–G) and corresponding quantification (H) of whole-tissue (gastrocnemius muscle, cut into 2 slices of equal thickness) viability (red, viable tissue) by triphenyltetrazolium chloride (TTC) staining 4 weeks after transplantation in vehicle (D; red in H), mMAPC-U (E; black in H), mBMC (F; gray in H), and mMAPC-VP (G; blue in H) groups. (I–L) Sirius red–stained cross sections of gastrocnemius muscle 5 weeks after transplantation of vehicle- (I), mMAPC-U– (J), mBMC- (K), or mMAPC-VP–injected (L) animals. All analyses were performed on 6–12 mice per group. The insets in E and J show a nonischemic muscle. *P < 0.05 versus vehicle for each corresponding time point. Scale bars: 500 μm (I–L). Original magnification, ×2 (D–G); ×0.66 (inset E); ×2.5 (inset J).